TRVI

AI Memo

Trevi Therapeutics

As of 2025-11-29/Confidence low/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2025-11-29 • Model: RankAlpha Sentiment AI

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

low

Horizon

6‑12m

Key catalyst

Advancement or readout from CNS pipeline • 2026-06-30

Expected move: -95%

Biggest risk

Failed trials, negative safety signals, or dilutive financings could drive the equity toward zero; cash runway and binary readouts are main downside drivers.

Invalidation

Break below $0 or thesis failure.

What would change my mind?

If Trevi secures positive clinical signals and extends runway without heavy dilution, shares could re-rate toward small-cap biotech multiples driven by program value and potential partnerships.

Research note

Recommendation

—

Confidence

low

As of

2025-11-29

Base target

p=60%

Bull target

p=20%

Bear target

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Regulatory setback or negative preclinical signal
Cash runway / financing event
If Trevi secures positive clinical signals and extends runway without heavy dilution, shares could re-rate toward small-cap biotech multiples driven by program value and potential partnerships.

BearKey bullets

Failed trials, negative safety signals, or dilutive financings could drive the equity toward zero; cash runway and binary readouts are main downside drivers.

WatchKey bullets

Advancement or readout from CNS pipeline

Summary

High-level snapshot

Recommendation

Model confidence

low

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $1 (p=60%)

Bull/Bear spread: -91% / -98%

Vs latest close: Bull -91% · Base -95% · Bear -98%

Scenario probabilities

Bull Target: $1 (p=20%)Base Target: $1 (p=60%)Bear Target: $0 (p=20%)

Commentary

Market tone is cautious-to-negative: investors focus on near-term financing and trial readouts while low liquidity amplifies moves. Press and filings emphasize funding needs and program timelines.

As of 2025-11-29 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

If Trevi secures positive clinical signals and extends runway without heavy dilution, shares could re-rate toward small-cap biotech multiples driven by program value and potential partnerships.

Bear Case

Failed trials, negative safety signals, or dilutive financings could drive the equity toward zero; cash runway and binary readouts are main downside drivers.

Drivers

Scannable catalysts and supporting factors

Regulatory setback or negative preclinical signal
Cash runway / financing event

Scenarios

Bull Target (Scenario probability)

$1 / p=20% prob

Base Target (Scenario probability)

$1 / p=60% prob

Bear Target (Scenario probability)

$0 / p=20% prob

Price $14 as of 2026-06-02

Nearest Scenario: Bull (∆ 91%)

Targets vs latest close: Bull -91% · Base -95% · Bear -98%

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-06-30
Advancement or readout from CNS pipeline
Potential clinical data update or program decision for lead CNS asset could materially move the stock; Trevi focuses on CNS candidates [#10Qp12].
Prob 30.00% • Move 40.00% • Priced-in 20.00%

Short-term Catalysts

Next few weeks

Regulatory setback or negative preclinical signal
2026-12-31
Adverse safety/efficacy data from trials or regulatory feedback could trigger sharp downside [#PR-2025-09-12].
Prob 20% • Move -50% • Priced-in 10%

Long-term Catalysts

Months to a year

Cash runway / financing event
2026-03-31
Need for additional financing or successful raise alters dilution expectations and valuation [#10Qp12].
Prob 50% • Move 30% • Priced-in 50%

Risks

No risks

Peers

Symbol	Summary
CLNN	Clinical-stage neuropsychiatric company; comparable binary data-dependency and capital needs.
VYGR	Biotech with CNS and orphan programs; subject to similar regulatory and trial-readout catalysts.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment AI
Analysis date: 2025-11-29

AI Stock Memo: TRVI - Trevi Therapeutics - RankAlpha